KIT and gastrointestinal stromal tumor: The majority of patients with advanced GIST ultimately become resistant to tyrosine kinase inhibitor (TKI) due to secondary KIT or PDGFRA mutations (Gebreyohannes et al., 2019; Huang et al., 2020).